We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

RenovoRx Inc (RNXT) USD0.0001

Sell:$1.31 Buy:$1.50 Change: $0.08 (6.15%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$1.31
Buy:$1.50
Change: $0.08 (6.15%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
Sell:$1.31
Buy:$1.50
Change: $0.08 (6.15%)
Market closed |  Prices as at close on 27 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in delivering its targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The Company’s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) utilizes chemotherapeutics. RenovoTAMP combines its patented delivery system, RenovoCath, with small molecule chemotherapeutic agents, which can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. Its first product candidate, RenovoGem, is a drug /device combination consisting of intra-arterial gemcitabine and RenovoCath. RenovoGem has been developed for the treatment of two rare diseases: pancreatic cancer and cholangiocarcinoma (CCA). It has completed the first of two planned interim analyses of the ongoing open-label Phase III TIGeR-PaC clinical trial.

Contact details

Address:
333 W Santa Clara St Ste 900
SAN JOSE
95113-1716
United States
Telephone:
+1 (408) 8002649
Website:
https://renovorx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RNXT
ISIN:
US75989R1077
Market cap:
$14.76 million
Shares in issue:
10.69 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ramtin Agah
    Chairman of the Board, Co-Founder, Chief Medical Officer
  • Shaun Bagai
    Chief Executive Officer, Director
  • Ronald Kocak
    Principal Financial Officer and Accounting Officer, Vice President, Controller
  • Leesa Gentry
    Chief Clinical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.